Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar S, Arya S, Mahajan A, Agarwal A, Purandare N, Rangarajan V, Balaji A, Chaudhari SV, Banavali S, Kannan S, Bhattacharjee A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Pantvaidya G, Nair D, Nair S, Deshmukh A, Thiagarajan S, Mathrudev V, Manjrekar A, Dhumal S, Maske K, Bhelekar AS, Nawale K, Chandrasekharan A, Pande N, Goel A, Talreja V, Simha V, Srinivas S, Swami R, Vallathol DH, Dsouza H, Shrirangwar S, Turkar S, Abraham G, Thanky AH, Patel U, Pandey MK, Prabhash K. Patil VM, et al. Among authors: pande n. Cancer. 2019 Sep 15;125(18):3184-3197. doi: 10.1002/cncr.32179. Epub 2019 May 31. Cancer. 2019. PMID: 31150120 Free article. Clinical Trial.
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, D'Cruz AK, Banavali S, Pai PS, Chaturvedi P, Chaukar D, Pande N, Chandrasekharan A, Talreja V, Vallathol DH, Mathrudev V, Manjrekar A, Maske K, Bhelekar AS, Nawale K, Kannan S, Gota V, Bhattacharjee A, Kane S, Juvekar SL, Prabhash K. Noronha V, et al. Among authors: pande n. J Clin Oncol. 2018 Apr 10;36(11):1064-1072. doi: 10.1200/JCO.2017.74.9457. Epub 2017 Dec 8. J Clin Oncol. 2018. PMID: 29220295 Clinical Trial.
Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.
Joshi A, Patil V, Noronha V, Dhumal S, Pande N, Chandrasekharan A, Turkar S, DSouza H, Shrirangwar S, Mahajan A, Arya S, Juvekar S, BhattaCharjee A, Prabhash K. Joshi A, et al. Among authors: pande n. Oral Oncol. 2017 Dec;75:54-60. doi: 10.1016/j.oraloncology.2017.10.018. Epub 2017 Nov 5. Oral Oncol. 2017. PMID: 29224823 Clinical Trial.
Rechallenge temozolomide in glioma: A case series from India.
Patil VM, Tonse R, Kothari R, Chandrasekaran A, Pande N, Epari S, Gupta T, Jalali R. Patil VM, et al. Among authors: pande n. Indian J Cancer. 2017 Jan-Mar;54(1):368-371. doi: 10.4103/ijc.IJC_173_17. Indian J Cancer. 2017. PMID: 29199725 Free article.
Influence of Hypothyroidism After Chemoradiation on Outcomes in Head and Neck Cancer.
Patil VM, Noronha V, Joshi A, Bhattacharjee A, Goel A, Talreja V, Chandrasekharan A, Pande N, Mandal T, Ramaswamy A, Prabhash K. Patil VM, et al. Among authors: pande n. Clin Oncol (R Coll Radiol). 2018 Oct;30(10):675. doi: 10.1016/j.clon.2018.07.002. Epub 2018 Jul 19. Clin Oncol (R Coll Radiol). 2018. PMID: 30033049 No abstract available.
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma.
Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Patil VM, et al. Among authors: pande n. ESMO Open. 2017 Apr 27;2(1):e000168. doi: 10.1136/esmoopen-2017-000168. eCollection 2017. ESMO Open. 2017. PMID: 28761735 Free PMC article.
Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapy.
Noronha V, Patil V, Joshi A, Chougule A, Bhattacharjee A, Kumar R, More S, Goud S, Karpe A, Ramaswamy A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Noronha V, et al. Among authors: pande n. Ecancermedicalscience. 2017 Oct 24;11:776. doi: 10.3332/ecancer.2017.776. eCollection 2017. Ecancermedicalscience. 2017. PMID: 29104613 Free PMC article.
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
Joshi A, Noronha V, Patil VM, Chougule A, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Joshi A, et al. Among authors: pande n. Chemother Res Pract. 2017;2017:8196434. doi: 10.1155/2017/8196434. Epub 2017 Oct 23. Chemother Res Pract. 2017. PMID: 29201462 Free PMC article.
96 results